Related Experiment Video
Updated: Apr 29, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
[Acute generalized exanthematous pustulosis]
1Univ.-Klinik für Dermatologie und Venerologie, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Österreich, alexis.sidoroff@i-med.ac.at.
Clinical Features:
Acute generalized exanthematous pustulosis (AGEP) is a reaction pattern mostly caused by drugs. It is characterized by the rapid occurrence of dozens to thousands pinhead-sized, non-follicular, sterile pustules on a slightly edematous erythematous base, commonly with accentuation in the major flexures and usually accompanied by a facial edema, fever and leukocytosis. Histology reveals spongiform subcorneal and/or intraepidermal pustules, an inflammatory infiltrate consisting of neutrophils and often eosinophils and frequently a marked edema of the papillary dermis.
Triggers:
Even if in single case reports a large number of drugs has been described as triggers for AGEP, larger studies have revealed a list with an elevated risk to cause the reaction which includes antibacterial agents like ampicillin/amoxicillin, quinolones, pristinamycin, anti-infective sulfonamides, the antimycotic drug terbinafine, (hydroxy)chloroquine, and diltiazem. In some cases infections have been reported as triggers.
Clinical Course, Prognosis And Treatment:
AGEP is an acute and--especially in patients with concomitant diseases--sometimes severe reaction. Withdrawal of the causative agent usually leads to a rapid and complete resolution--even without further specific therapy.
Related Concept Videos
Acne Infection
Staphylococcal Skin Infections
Hypersensitivity Reactions: Immune-Complex Reactions
Atypical Pneumonia
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

